GDR 3.38 -0.375 -10.00% : Genedrive PLC – MSN Money
Genedrive PLC (LON GDR) is a molecular diagnostics company that specializes in the development and commercialization of a point-of-care molecular platform for the diagnosis of infectious diseases, genotyping, pathogen detection, and other applications.
They are known for their Genedrive® HCV-ID test, which has received CE-IVD Certification and is available in Africa and the Asia Pacific region.
The company has been actively expanding its product range, including the Genedrive® MT-RNR1 ID Kit, which is the world’s first point-of-care genetic test aimed at reducing the risk of aminoglycoside-induced hearing loss. This test has seen initial orders from multiple countries and is being adopted by NHS hospitals for routine use.
Additionally, Genedrive has achieved UKCA marking for their new Genedrive® CYP2C19 test, which aids in the treatment management of stroke patients and is preparing for NHS introduction³. The company’s mission is to create easy-to-use, point-of-care pharmacogenetic tests that can be used in time-critical settings to directly improve clinical outcomes.
genedrive plc is based in Manchester, United Kingdom. The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc. With an historical founding in the provision of contract research services to Pharmaceutical and Biotech companies, the business was renamed genedrive plc (LON:GDR) in July 2016 to reflect the new direction of the company targeting molecular diagnostic requirements at the point of need. The legacy contract research services divisions were divested in June 2018.
genedrive plc achieves manufacturing milestones for SARS-CoV-2 test